<DOC>
	<DOCNO>NCT00307008</DOCNO>
	<brief_summary>Streptococcus pneumoniae bacteria normally live upper respiratory tract human . However , bacteria also cause severe infectious disease pneumonia , septicemia meningitis . Elderly subject especially vulnerable infection , disease result death . The currently available license Streptococcus pneumoniae vaccine recommend prevention pneumococcal disease individual age 65 . However , antibody level elicit vaccine , always satisfactory elderly people . To overcome problem , GlaxoSmithKline Biologicals currently develop candidate vaccine hop work well currently available vaccine . As first step development , present study conduct order evaluate immune response currently market vaccine .</brief_summary>
	<brief_title>Study Evaluate Response Rate Licensed Pneumovax 23™ Elderly Population .</brief_title>
	<detailed_description>Since influenza vaccination recommend age range study population , Fluarix™ ( GlaxoSmithKline Biologicals ) vaccine offer free charge study period ( 3 consecutive year ) , use Investigators accord national vaccination schedule/practice . The Protocol Posting update order comply FDA Amendment Act , Sep 2007</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion Subjects investigator believe comply requirement protocol . A male female &gt; = 65 year time first vaccination . Written inform consent obtain subject . Exclusion criterion Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period participation another pharmaceutical/vaccine study . Previous vaccination Streptococcus pneumoniae . History administration experimental vaccine contain MPL QS21 . History allergic disease reaction likely exacerbate component vaccine . Planned administration vaccine foreseen study protocol within 2 week first dose vaccine , exclude influenza vaccine administer time , include coadministration Pneumovax23™ . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . Current serious neurologic mental disorder . Inflammatory process know chronic active infection ( e.g.Hep B , C ) . All malignancy ( exclude nonmelanic skin cancer ) lymphoproliferative disorder diagnose treat actively past 5 year . Acute disease time enrolment . Chronic disease might preclude participation whole study .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Prophylaxis Invasive pneumococcal disease pneumonia</keyword>
</DOC>